Hyun T. Lee
Nung-dong, Republic of Korea
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Structural Insights into the ADCC Mechanism and Resistance of Mogamulizumab, a First-in-Class Anti-CCR4 Therapy for Cutaneous T Cell Lymphoma.
Journal: International journal of molecular sciences
Published: May 09, 2025
Molecular basis of PD-1 blockade by dostarlimab, the FDA-approved antibody for cancer immunotherapy.
Molecular basis of PD-1 blockade by dostarlimab, the FDA-approved antibody for cancer immunotherapy.
Journal: Biochemical and biophysical research communications
Published: February 03, 2022
High-resolution structure of the vWF A1 domain in complex with caplacizumab, the first nanobody-based medicine for treating acquired TTP.
Journal: Biochemical and biophysical research communications
Published: June 04, 2021
Crystal structure of CD38 in complex with daratumumab, a first-in-class anti-CD38 antibody drug for treating multiple myeloma.
Journal: Biochemical and biophysical research communications
Published: December 14, 2020
Crystal structure of PD-1 in complex with an antibody-drug tislelizumab used in tumor immune checkpoint therapy.
Journal: Biochemical and biophysical research communications
Published: April 21, 2020
A small-sized protein binder specific for human PD-1 effectively suppresses the tumour growth in tumour mouse model.
Journal: Journal of drug targeting
Published: September 17, 2019
Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology.
Journal: Molecules (Basel, Switzerland)
Published: March 04, 2019
Structural Biology of the TNFα Antagonists Used in the Treatment of Rheumatoid Arthritis.
Journal: International journal of molecular sciences
Published: February 08, 2018
BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus.
Journal: Nature communications
Published: September 16, 2017
Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab.
Journal: Scientific reports
Published: March 29, 2017
Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy.
Journal: Nature communications
Published: July 15, 2016
Showing 1-11 of 11
Last Updated: 09/26/2026